ReShape Lifesciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

ReShape Lifesciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-183.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-183.0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

Apr 18

ReShape wins FDA clearance for device used in weight loss surgery

Aug 10

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Mar 31

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Dec 09

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Aug 24

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: RSLS şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: RSLS şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

ReShape Lifesciences Piyasaya Karşı Temettü Getirisi

RSLS temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (RSLS)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (RSLS) (3 yıla kadar)	n/a

Önemli Temettü: RSLS şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, RSLS şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: RSLS şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: RSLS herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

ReShape Lifesciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$3.12 loss per share (vs US$59.37 loss in 3Q 2023)

ReShape Lifesciences Inc. to Report Q3, 2024 Results on Nov 14, 2024

ReShape Lifesciences Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences Inc. announced that it expects to receive $0.833333 million in funding

Second quarter 2024 earnings released: US$0.063 loss per share (vs US$1.08 loss in 2Q 2023)

ReShape Lifesciences Inc. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024

The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System

Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023

ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq

ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023

ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus EPS estimates upgraded to US$16.50 loss

Full year 2022 earnings: EPS misses analyst expectations

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Price target decreased to US$1.03

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021)

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. announced delayed 10-Q filing

Price target decreased to US$3.08

Insufficient new directors

Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures

ReShape wins FDA clearance for device used in weight loss surgery

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq

ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022

ReShape Lifesciences Inc. announced delayed 10-Q filing

ReShape Lifesciences Inc. announced delayed annual 10-K filing

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020)

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020)

High number of new directors

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$12.00

ReShape Lifesciences Inc. (OTCPK:RSLS) completed the acquisition of Obalon Therapeutics, Inc. (NasdaqCM:OBLN) in a reverse merger transaction.

ReShape Lifesciences Inc. (OTCPK:RSLS) entered into an agreement to acquire Obalon Therapeutics, Inc. (NasdaqCM:OBLN).

ReShape Lifesciences Inc. to Report Q2, 2020 Results on Aug 13, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin